Description
Israpafant is a selective antagonist for the platelet-activating factor receptor (IC50 = 0.8nM). Israpafant inhibits PAF-induced Human platelet aggregation. Israpafant inhibits the activation of eosinophil cells and consequently delays the development of immune responses. Israpafant also has anti-nephrotoxic properties and to mobilize calcium transport